Studies Report Findings in Crohn's Disease and Parkinson's Disease
SAN DIEGO--(BUSINESS WIRE)--Dec. 5, 2006--Illumina (NASDAQ:ILMN)today announced that important results from genotyping research inCrohn's disease and Parkinson's disease (PD) using Illumina'sInfinium(R) HumanHap300 BeadChip were published in peer-reviewedjournals, Science and The Lancet.
Using the HumanHap300 BeadChip, a consortium of United States andCanadian researchers uncovered a breakthrough discovery inInflammatory Bowel Disease (IBD). The study's authors, who representthe National Institute of Diabetes & Digestive & Kidney Diseases(NIDDK) IBD Genetics Consortium, found that variants in a gene thatcodes for part of the immune cell receptor for interleukin-23 (IL-23R)are strongly associated with Crohn's disease and ulcerative colitis,collectively called IBD. Findings from this study appeared in theDecember 1 issue of Science, and will be discussed during anIllumina-sponsored Webinar with lead authors on Monday, January 15,2007. To register for this event, please visit www.illumina.com/infinium/webinars.
Under the direction of Peter Gregersen, M.D., and Annette Lee,Ph.D., genotyping for the IBD study was conducted on Illumina'sgenetic analysis system at The Robert S. Boas Center for Genomics andHuman Genetics at the Feinstein Institute for Medical Research, NorthShore-Long Island Jewish Health System.
Senior author Judy H. Cho, M.D., Associate Professor of Medicineand Genetics at Yale School of Medicine said, "Our team chose to workwith Illumina's HumanHap300 BeadChip because it provided outstandingquality and genomic coverage necessary to efficiently and effectivelyidentify the genetic basis behind IBD." First author of the study,Richard H. Duerr, M.D., Associate Professor of Medicine and HumanGenetics at the University of Pittsburgh added, "More importantly, dueto the speed and accuracy of the technology and the significance ofthe results, only 10 months elapsed between initiating the study andpublication."
A second study published in the September 27 online issue of TheLancet also employed the HumanHap300 BeadChip, which completed one ofthe first large-scale studies of genetic variation in PD. Led byAndrew Singleton, Ph.D., of the National Institute of Aging (NIA),results from the study will help to pave the way towards continuedresearch in PD and other neurological diseases.
"In less than a year after the International HapMap Project'sconclusion, and within eight months of the HumanHap300 BeadChiplaunch, the new discoveries in Crohn's and Parkinson's disease signifythe power of the Infinium whole-genome association technology touncover the genetic basis of complex diseases," said Jay Flatley,Illumina President and Chief Executive Officer. "We believe Illumina'sBeadChips set the gold standard in the industry for performance,quality and coverage."
About the HumanHap300 BeadChip
Illumina's HumanHap300 BeadChip enables whole-genome genotyping ofover 317,000 tagSNP markers derived from the International HapMapProject (www.hapmap.org). The BeadChip is powered by the InfiniumAssay which enables intelligent SNP selection utilizing tagSNPs. TheHumanHap300 is also available in a two-sample BeadChip(HumanHap300-Duo), or can be customized with up to 60,800 additionalcustom SNPs (HumanHap300-Duo+). For more information about Infiniumtechnology, please visit www.illumina.com/infinium.
About Illumina
Illumina (www.illumina.com) develops and markets next-generationtools for the large-scale analysis of genetic variation and function.The Company's proprietary BeadArray technology - used in leadinggenomics centers around the world - provides the throughput, costeffectiveness and flexibility necessary to enable researchers in thelife sciences and pharmaceutical industries to perform the billions oftests necessary to extract medically valuable information fromadvances in genomics and proteomics. This information will help pavethe way to personalized medicine by correlating genetic variation andgene function with particular disease states, enhancing drugdiscovery, allowing diseases to be detected earlier and morespecifically, and permitting better choices of drugs for individualpatients.
"Safe Harbor" Statement under the Private Securities LitigationReform Act of 1995: This release may contain forward-lookingstatements that involve risks and uncertainties. Among the importantfactors that could cause actual results to differ materially fromthose in any forward-looking statements are the costs and outcome ofIllumina's litigation with Affymetrix, the Company's ability to scaleand integrate CyVera technology, the ability to further scale oligosynthesis output and technology to satisfy market demand deriving fromthe Company's collaboration with Invitrogen, Illumina's ability tofurther develop and commercialize its BeadArray technologies and todeploy new gene expression and genotyping products and applicationsfor its platform technology, to manufacture robust Sentrix(R) arrays -including HumanHap BeadChips - and Oligator(R) oligonucleotides, andother factors detailed in the Company's filings with the Securitiesand Exchange Commission including its recent filings on Forms 10-K and10-Q or in information disclosed in public conference calls, the dateand time of which are released beforehand. Illumina disclaims anyintent or obligation to update these forward-looking statements beyondthe date of this release.
MULTIMEDIA AVAILABLE:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5287558
CONTACT: Illumina
Jay Flatley, President & CEO
858-202-4501
jflatley@illumina.com
or
Maurissa Bornstein, Manager, Public Relations
858-332-4055
mbornstein@illumina.com
SOURCE: Illumina